441 related articles for article (PubMed ID: 29167275)
1. Residual Convolutional Neural Network for the Determination of
Chang K; Bai HX; Zhou H; Su C; Bi WL; Agbodza E; Kavouridis VK; Senders JT; Boaro A; Beers A; Zhang B; Capellini A; Liao W; Shen Q; Li X; Xiao B; Cryan J; Ramkissoon S; Ramkissoon L; Ligon K; Wen PY; Bindra RS; Woo J; Arnaout O; Gerstner ER; Zhang PJ; Rosen BR; Yang L; Huang RY; Kalpathy-Cramer J
Clin Cancer Res; 2018 Mar; 24(5):1073-1081. PubMed ID: 29167275
[No Abstract] [Full Text] [Related]
2. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
3. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
Choi KS; Choi SH; Jeong B
Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
[TBL] [Abstract][Full Text] [Related]
4. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
5. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics.
Choi YS; Bae S; Chang JH; Kang SG; Kim SH; Kim J; Rim TH; Choi SH; Jain R; Lee SK
Neuro Oncol; 2021 Feb; 23(2):304-313. PubMed ID: 32706862
[TBL] [Abstract][Full Text] [Related]
6. Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
[TBL] [Abstract][Full Text] [Related]
7. Natural language processing to predict isocitrate dehydrogenase genotype in diffuse glioma using MR radiology reports.
Kim M; Ong KT; Choi S; Yeo J; Kim S; Han K; Park JE; Kim HS; Choi YS; Ahn SS; Kim J; Lee SK; Sohn B
Eur Radiol; 2023 Nov; 33(11):8017-8025. PubMed ID: 37566271
[TBL] [Abstract][Full Text] [Related]
8. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
9. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Isocitrate Dehydrogenase 1 Status Prediction in Grade II/III Glioma Based on Magnetic Resonance Images: A Transfer Learning Strategy.
Zhang J; Wang Y; Yang Y; Han Y; Yu Y; Hu Y; Liang S; Sun Q; Shang D; Bi J; Cui G; Yan L
J Comput Assist Tomogr; 2024 May-Jun 01; 48(3):449-458. PubMed ID: 38271541
[TBL] [Abstract][Full Text] [Related]
11. External Validation of a Convolutional Neural Network for IDH Mutation Prediction.
Hrapșa I; Florian IA; Șușman S; Farcaș M; Beni L; Florian IS
Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454365
[No Abstract] [Full Text] [Related]
12. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
14. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
Bangalore Yogananda CG; Shah BR; Vejdani-Jahromi M; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
Neuro Oncol; 2020 Mar; 22(3):402-411. PubMed ID: 31637430
[TBL] [Abstract][Full Text] [Related]
15. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
16. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
[TBL] [Abstract][Full Text] [Related]
17. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
Patel SH; Poisson LM; Brat DJ; Zhou Y; Cooper L; Snuderl M; Thomas C; Franceschi AM; Griffith B; Flanders AE; Golfinos JG; Chi AS; Jain R
Clin Cancer Res; 2017 Oct; 23(20):6078-6085. PubMed ID: 28751449
[No Abstract] [Full Text] [Related]
18. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
[TBL] [Abstract][Full Text] [Related]
19. Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Cao M; Suo S; Zhang X; Wang X; Xu J; Yang W; Zhou Y
Biomed Res Int; 2021; 2021():1235314. PubMed ID: 33553421
[TBL] [Abstract][Full Text] [Related]
20. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
